Pfizer carries one of Big Pharma's fattest yields while Merck burns cash on deals to secure its next growth era. Which ...

Pfizer said it cut its full-year revenue expectation for its Covid products to $4 billion, down from around $5 billion ...

The stock's yield is more than six times the S&P 500 average.

The company reiterated its recent reduction in full-year sales guidance by $9 billion as it doubled down on efforts to trim ...

Pfizer will reduce its costs by $2.5 billion in another round of cutbacks, which will kick in next year and run through 2029. The New York company unveiled the plan in its second-quarter earnings ...

So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes ...

Q2 operational sales growth of 1% was driven by higher sales of older medicines, including cancer drug Padcev (+23% ...

Pfizer's $31 billion bond sale ranks among the largest ever, but it's still only half the size, adjusted for inflation, of ...

Construction delays at MetroLoft's conversion of the Pfizer building could endanger success at the Midtown East project ...